The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face competition from cheaper generics.
Related Posts
Powell says the Fed doesn’t need to be ‘in a hurry’ to reduce interest rates
“The strength we are currently seeing in the economy gives us the ability to approach our decisions carefully,” Powell said.
Airline executives set to defend seat fees before Senate panel
Executives from American, United, Delta, Frontier and Spirit are set to testify before a Senate panel Wednesday about their seating fees.
SoftBank in talks to invest up to $25 billion in OpenAI
SoftBank is in talks to invest up to $25 billion in OpenAI, which would make it the company’s biggest backer, CNBC has confirmed.